CD33 and Thrombocytopenia: However, because it is expressed on normal myeloid lineage cells, we evaluated potential hematological side effects of M2T-CD33, given prior reports of thrombocytopenia with hemorrhagic events and other cytopenias in patients treated with GO [58, 59].